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Background: Safety and efficacy of tamsulosin and tadalafil for men with benign
prostatic enlargement (BPE) and/or erectile dysfunction (ED) are defined. However,
there are only a few pilot studies on combination therapy with these drugs for men with
lower urinary tract symptom (LUTS)/BPE and ED. Moreover, preliminary reports are
limited to 12 wk, without any information about subsequent therapies.
Objective: To evaluate the impact of discontinuation of tamsulosin versus tadalafil
12 wk after combination therapy.
Design, setting, and participants: Fifty consecutive patients with moderate-to-severe
LUTS (International Prostate Symptom Score [IPSS] > 7) and mild-to-severe ED (Inter-
national Index of Erectile Function-5 [IIEF-5] < 22) were treated with combination
therapy (tamsulosin 0.4 mg/d plus tadalafil 5 mg/d) for 12 wk. After 12 wk, 25 patients
discontinued tamsulosin (Group TAD), while 25 patients discontinued tadalafil (Group
TAM).
Outcome measurements and statistical analysis: Efficacy variables were IPSS (total,
voiding, storage) and IIEF-5. Paired samples t test and analysis of variance were used.
Results and limitations: Groups TAD and TAM presented similar features (age, BMI,
metabolic profile) including symptoms scores at baseline. Similar and significant
improvements in IPSS (total, voiding, and storage) and IIEF-5 were recorded in both
groups after 12 wk of combination therapy (all p < 0.001). Total IPSS was similar
between the two groups at the end of the trial. However, we found between-group
significant differences from baseline to 24 wk and from 12 to 24 wk in storage-IPSS
(Group TAD: –3.32 vs Group TAM: –1.24, p = 0.002; Group TAD: +0.24 vs Group at: Department of Minimally Invasive and Robotic Urologic Surgery and
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TAM: +1.20, p = 0.040, respectively) and in IIEF-5 (Group TAD: +4.64 vs Group
TAM: +0.16, p < 0.001; Group TAD: –1.64 vs Group TAM: –4.40, p = 0.003). No significant
treatment-related adverse event was recorded in both groups.
Conclusions: After 12 wk of combination therapy, monotherapy with tadalafil for further
12 wk allows to preserve the improvement of storage IPSS and IIEF-5, in addition to total
IPSS.
Patient summary: In this report we evaluated the discontinuation of tamsulosin or
tadalafil after 12 wk of combination therapy. We found that tadalafil monotherapy, for a
further 12 wk, aids in retaining the improvement of storage symptoms and erectile
function.
© 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.
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Lower urinary tract symptoms (LUTSs) and erectile dysfunc-
tion (ED) are significant health concerns that will increase in
the next years in relation to the aging of the population.
Both conditions have a significant impact on the overall
male quality of life (QoL). LUTS, including voiding, storage,
and postmicturition symptoms, secondary to benign pros-
tatic hyperplasia (BPH) is frequently reported in middle-
aged or older men. They range from mild to severe and could
have a major impact on patients’ QoL [1,2].
ED, defined as a persistent inability to achieve and
maintain an erection sufficient for satisfactory sexual per-
formance, is generally considered the result of para-aging
factors and its prevalence has increased from 5% for men in
their forties to 15% for those aged 70 yr [3].
Several large-scale epidemiological studies in different
population have demonstrated a relationship between LUTS
and ED in aging men that is independent of the effects of age
or other comorbidities; particularly, men with severe LUTS
presented an incidence of ED about three times higher than
those without LUTS [1,4].
Today, although the molecular and pathological
pathways potentially linking LUTS and ED are not clearly
defined, several possible biological mechanisms includ-
ing an altered nitric oxide/cyclic guanosine monopho-
sphate pathway, an altered RhoA/Rho kinase signaling,
systemic inflammation, pelvic ischemia, autonomic
adrenergic hyperactivity, or overactivity have been
investigated [5–8].
LUTS/BPH medical treatment may also have a significant
impact on erectile function (EF). Several randomized con-
trolled trials demonstrated that alpha-blockers (ABs) and 5-
alpha reductase inhibitors, the most commonly prescribed
drugs for managing patients with LUTS/BPH, can be associ-
ated with sexual adverse effects (AEs) such as decreased or
loss of libido, ED, and ejaculatory dysfunction [9–11].
Phosphodiesterase type 5 inhibitors (PDE5-Is), the first-
line therapy for ED, and particularly tadalafil 5 mg once
daily, have been approved and considered an effective and
well-tolerated treatment for LUTS [10].
Although the exact mechanism of action of PDE5-Is remains
unclear, several preclinical and clinical trials have shown that
they can reduce the smooth muscle tone of detrusor, prostate,
and urethra together with an increased blood perfusion and
oxygenation in the lower urinary tract; besides, its possiblePlease cite this article in press as: Sebastianelli A, et al. Which D
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Observational Trial. Eur Urol Focus (2019), https://doi.org/10.1016effect on chronic inflammation in the prostate and bladder has
been proposed [12–15].
Safety and efficacy of PDE5-Is are well defined and
combination therapy of PDE5-Is and ABs, particularly tam-
sulosin, the only AB approved by the Food and Drug Admin-
istration in combination with tadalafil, has shown to have
an additive favorable effect on International Prostate Symp-
tom Score (IPSS), International Index of Erectile Function-5
(IIEF-5) score, and maximum flow rate (Qmax) compared
with monotherapy alone [16]. So far, the recent possibility
to manage both LUTS and ED by PDE5-i alone or in combi-
nation with tamsulosin may open up new management
strategies, considering that treatment of one condition
may have an impact on the other. However, although a
combination therapy is considered a promising and tailored
approach seeking a balance between efficacy and tolerabil-
ity in patients with LUTS, there are no data on when to move
from a single-drug management to a combination approach
and what are the possible changes in efficacy by switching
from one treatment modality to another [17].
The aim of this observational study is to evaluate the
impact of discontinuation of tamsulosin (0.4 mg) or tada-
lafil (5 mg) after 12 wk of combination therapy in patients
with LUTS and ED.
2. Material and methods
2.1. Design and participants
A prospective observational trial was designed and per-
formed. Across 12 mo, 50 consecutive patients with ED
and LUTS suggestive of benign prostatic obstruction
(BPO) were enrolled.
Inclusion criteria were age >40–80 yr, mild to severe
ED (IIEF-5 < 22), moderate to severe LUTS (IPSS > 7), and
Qmax > 5 ml/s (obtained from a uroflowmetry assess-
ment). Exclusion criteria were hypersensitivity to tada-
lafil or tamsulosin, prostatic cancer or suspected with
prostate-specific-antigen > 4.0 ng/ml, bladder lithiasis,
previous prostatic surgery, urinary tract infection, neuro-
genic bladder, finasteride or dutasteride use within 6 mo,
and a clinical history of urethral and/or proven bladder
neck obstruction.
The study was performed in accordance with applicable
laws and regulations, good clinical practices, and ethical
principles as described in the Declaration of Helsinki.rug to Discontinue 3 Months After Combination Therapy of
ymptom and Erectile Dysfunction? Results of a Prospective
/j.euf.2019.09.015
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(Ethics Committee Approval OSS.15.031). All men provided
written informed consent before initiating any trial proce-
dure or therapy.
The assessment of patients included age, body mass
index, waist circumference, blood pressure, clinical labora-
tory parameters, digital rectal examination, IPSS [18], IIEF-5
score [19], uroflowmetry, and postvoid residue (PVR) vol-
ume (evaluated with abdominal ultrasound immediately
after voiding for uroflowmetry). The IPSS storage and void-
ing subscores, nocturia question, and IPSS-QoL index were
also assessed.
After a 4-wk wash-out period from previous therapies
for BPO and a 2-wk run-in period with tamsulosin 0.4 mg,
patients were treated in two urologic centers with combi-
nation therapy of tamsulosin 0.4 mg/d and tadalafil 5 mg/d
for 12 wk.
After 12 wk, the tamsulosin therapy was discontinued
in one center, leaving 25 patients with tadalafil 5 mg/d
alone (Group TAD), whereas tadalafil was discontinued in
the other center, leaving 25 patients with tamsulosin
0.4 mg/d only (Group TAM; Fig. 1).
Patients were evaluated at screening time, after 12 wk of
combination therapy, and after 12 wk of monotherapy.
Patients were instructed to self-administer the study
drugs at the same time every day before sleep, without
restrictions of food intake or timing of sexual activity.
Patients were considered compliant if at least 90% of the
drug amount was taken. Safety was assessed by evaluating
patient-reported AEs, orthostatic vital signs, PVR, uroflow-
metry, and clinical laboratory parameters. Patients with
incomplete data sets were excluded from statistical
analysis.
The variables considered for measuring the efficacy of
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Fig. 1 – Disposition of patients. Patient Consolidated Standards of Reporting Tr
PLA = placebo.
aPatients who did not perform combination therapy of tadalafil plus tamsulos
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the improving of Qmax. All follow-up visits, including
uroflowmetry, were performed in the morning (from
8:00 am to 12:00 pm).
2.2. Statistical analysis
Differences between combination therapy and the two
groups switched to monotherapy were calculated by an
unpaired sample t test at baseline, 12 wk, and 24 wk,
respectively. Mean changes between baseline and 12 wk
and those between 12 and 24 wk were assessed by a paired
sample t test for each treatment group. Between-group
differences in change from baseline to 12 wk and from
12 to 24 wk were measured by one-way analysis of variance
(ANOVA). All statistical analyses were performed with SPSS
(SPSS Inc., Chicago, IL, USA). A p value of 0.05 or less was
considered statistically significant.
3. Results
A total of 50 patients were treated with combination
therapy of tamsulosin 0.4 mg/d plus tadalafil 5 mg/d for
12 wk [20]. Subsequently, 25 patients continued tadalafil 5
mg/d (Group TAD) and 25 continued tamsulosin 0.4 mg/d
(Group TAM) only, for a further 12 wk. A Consolidated
Standards of Reporting Trials (CONSORT) flowchart is
shown in Fig. 1. All participants completed the study.
Compliance with dosing requirements was over 90% in
both groups. Both treatment groups were well balanced,
without significant differences in metabolic features, age,
and BPO-related characteristics (Table 1). The overall
improvement from baseline to the first checkpoint after
12 wk of combination therapy (tadalafil plus tamsulosin)








Patient decision = 5
Physician decision = 2
Group TAD + PLA
Tadalafil 5 mg + Placebo
n = 25
ials (CONSORT) diagram.
in for 12 weeks did not continue the study.
rug to Discontinue 3 Months After Combination Therapy of
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Table 1 – Patients’ baseline characteristics.
Group TAD (n = 25) Group TAM (n = 25)
Mean  standard deviation Minimum–Maximum Mean  standard deviation Minimum–Maximum p value
Age (yr) 64.4  8.3 48–77 67.0  7.8 47–78 0.314
Weight (kg) 77.3  8.2 67–85 75.9  9.5 66–83 0.306
Body mass index (kg/m2) 27.2  5.3 24–32 25.9  5.7 25–32 0.187
Abdominal obesity:
waist circumference (cm)
107.8  6.1 93–133 104.3  4.5 78–128 0.142
Triglycerides (mg/dl) 164.4  6.4 78–268 138.7  6.8 81–203 0.128
HDL cholesterol (mg/dl) 48.7  3.2 28–68 49.2  2.6 31–62 0.275
Glycemia (mg/dl) 123.2  4.5 79–224 107.7  5.7 79–215 0.124
IPSS base 18.1  5.8 8–29 19.6  6.1 11–32 0.369
IPSS voiding base 8.3  4.3 1–16 8.9  3.4 5–20 0.537
IPSS storage base 8.8  3.2 0–14 7.9  3.2 2–13 0.354
IPSS QoL base 3.9  0.9 3–6 3.8  1.2 2–6 0.686
IIEF-5 base 12.3  4.0 6–21 11.8  3.2 6–18 0.587
Qmax base (ml/s) 14.0  3.8 8.4–23.0 11.8  4.1 3.4–19.7 0.55
HDL = high-density lipoprotein; IIEF-5 = International Index of Erectile Function-5; IPSS = International Prostate Symptom Score; Qmax = maximum urinary flow
rate; QoL = quality of life.
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Qmax (all p < 0.001). Between-group ANOVA, comparing
Group TAD only versus Group TAM only, did not show
significant differences for total IPSS (p = 0.233), storage
IPSS (p = 0.235), voiding IPSS (p = 0.02); IIEF-5 (p = 0.412);
and Qmax (p = 0.908; Table 2). As shown in Table 3, after
12 wk of monotherapy, a statistically significant difference
was found between the two groups for mean IPSS storage
score (Group TAD: +0.24 vs Group TAM: +1.2; p = 0.040;
Fig. 2A), mean IIEF-5 score (Group TAD: –1.64 pts vs Group
TAM: –4.4; p = 0.003; Fig. 2B), and mean Qmax (Group TAD:
–2.41 ml/s vs Group TAM: –0.25 ml/s; p = 0.001; data not
shown). Conversely, total IPSS and voiding IPSS were simi-
lar after the switch from combination to monotherapy
(Fig. 3A and 3B). The proportion of patients reporting at
least one treatment-emergent AE (TEAE) was similar
between groups (TAD: 16% vs TAM: 20%; Table 4). TEAEs
were mild to moderate in severity, with the most common
being headache and back pain. There were no clinically
significant changes in laboratory measurements or vital
signs. No urinary retention was reported. None of the
patients discontinued therapy because of a TEAE.Table 2 – Change from baseline to 12 wk for Group TAD and Group TA
Group TAD (n = 25) 
Mean IPSS 12 wk
Delta3 M (baseline–12 wk)
10.4
–7.64
Mean IPSS voiding 12 wk
Delta3 M (baseline–12 wk)
4.52
–3.76
Mean IPSS storage 12 wk
Delta3 M (baseline–12 wk)
5.2
–3.56
Mean IPSS QoL 12 wk
Delta3 M (baseline–12 wk)
2.24
–1.72
Mean IIEF-5 12 wk
Delta3 M (baseline–12 wk)
18.6
+6.28
Mean Qmax 12 wk
Delta3 M (baseline–12 wk)
18.28
+4.27
IPSS = International Prostate Symptom Score; IIEF-5 = International Index of Erec
* Levels of significance are calculated with paired sample t test (p  0.05). The p
Please cite this article in press as: Sebastianelli A, et al. Which D
Tadalafil plus Tamsulosin for Men with Lower Urinary Tract S
Observational Trial. Eur Urol Focus (2019), https://doi.org/10.10164. Discussion
Currently, there are four PDE5-Is approved for ED treatment
which have been investigated for the treatment of LUTS
with or without ED in randomized double-blind clinical
trials. In a recent meta-analysis, combination of PDE5-is
and ABs improved the IIEF-5 score (+3.6; p < 0.001), IPSS
(–1.8; p = 0.05), and Qmax (+1.5 ml; p < 0.001) when com-
pared with ABs alone [21].
Theauthorsconcludedthat,althoughthecost-effectiveness
analysis of this treatment is needed, PDE5-Is are effective and
well tolerated either alone or in combination with ABs, partic-
ularly in young patients with severe LUTS/BPH. Moreover, a
recent prospective urodynamic study evaluating the impact of
daily tadalafil 5 mg on storage and voiding function in male
BPH patients showed that mean bladder outlet obstruction
index significantly decreased from 59.5 at baseline to 45.7 at
3 mo (p = 0.001), and to 42.9 at 12 mo (p < 0.001) [22].
Thus, tadalafil once daily, alone or in combination with
tamsulosin, is increasingly prescribed in clinical practice as
an effective therapy for LUTS/BPE and concomitant ED
[23,24].M.



















tile Function-5; Qmax = maximum urinary flow rate; QoL = quality of life.
 value indicates the level of significance as per analysis of variance.
rug to Discontinue 3 Months After Combination Therapy of
ymptom and Erectile Dysfunction? Results of a Prospective
/j.euf.2019.09.015
Table 3 – Change from 12 wk to 24 wk for TAD and TAM groups.
Group TAD (n = 25) Group TAM (n = 25) p value*
Mean IPSS 24 wk
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IPSS = International Prostate Symptom Score; IIEF-5 = International Index of Erectile Function-5; Qmax = maximum urinary flow rate; QoL = quality of life.

















Baseline Baseline12 wk 12 wk24 wk 24 wk
Switch to tamsulosin Switch to tamsulosinSwitch to tadalafil Switch to tadalafil
Fig. 2 – Change from baseline to 24 wk for Groups TAD and TAM.
Group TAD = discontinued tamsulosin; Group TAM, discontinued tadalafil; IIEF-5 = International Index of Erectile Function-5; IPSS = International
Prostate Symptom Score; Qmax = maximum urinary flow rate.
(A) (B)

























12 wk 24 wk Baseline 12 wk 24 wk
Fig. 3 – Change from baseline to 24 wk for the TAD and TAM groups. IPSS = International Prostate Symptom Score.
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ment of total IPSS (–7), voiding IPSS (–3.5), storage IPSS (–3),
IPSS-QoL (–1.8), IIEF-5 (+5.7), and Qmax (+4.2 ml/s; for all,
p < 0.001) after 12 wk of combination therapy. Indeed, as
we previously reported, combination therapy was associ-
ated with a better improvement of Qmax and voiding IPSS
compared with tadalafil alone [20].Please cite this article in press as: Sebastianelli A, et al. Which D
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Observational Trial. Eur Urol Focus (2019), https://doi.org/10.1016Interestingly, at the end of the study, after further
12 wk of monotherapy, patients in both groups shared
similar total IPSS, voiding IPSS, and IPSS-QoL scores, all
clinically meaningful improvements when compared
with baseline. Indeed, Dong et al [25] showed that tada-
lafil alone seemed to be efficient to improve voiding
subscore (–1.47) and IPSS-QoL (–0.35) compared withrug to Discontinue 3 Months After Combination Therapy of
mptom and Erectile Dysfunction? Results of a Prospective
/j.euf.2019.09.015
Table 4 – Summary of adverse events reported during the
treatment period (24 wk).
Group TAD
(n = 25), n (%)
Group TAM
(n = 25), n (%)
Any TEAEs 4 (16) 5 (20)
Serious AEs 0 (0.0) 0 (0.0)
Intensity
Mild 3 (12) 3 (12)
Moderate 1 (4) 2 (8)
Severe 0 (0.0) 0 (0.0)
Headache 2 (8) 2 (8)
Nasopharyngitis 0 (0.0) 1 (4)
Back pain 1 (4) 1(4)
Dizziness 0 (0.0) 0 (0.0)
Dyspepsia 1 (4) 0 (0.0)
Ejaculatory dysfunction 0 (0.0) 1 (4)
AEs = adverse events; TEAEs = treatment-emergent adverse events.
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vant, because a mean change less than 3 points in IPSS
was recorded.
In our study, patients in the TAD group experienced a
statistically significant but not clinically relevant (<1-point)
change in storage IPSS when compared with patients in the
TAM group. However, in both groups we observed a sta-
tistically and clinically significant improvement from base-
line. Our results confirmed the long-term effect of PDE5-i
treatment on LUTS, particularly storage LUTS and that this
effect is maintained for at least 12 wk when treatment is
suspended.
The urodynamic findings of Matsukawa et al [22] sup-
port our results. Indeed, in 49 patients who had detrusor
overactivity during cystometry at the baseline assessment,
uninhibited detrusor contractions disappeared in 15
(30.6%) after 3 mo (p = 0.02), and in 22 (44.9%) after
12 mo (p < 0.001) of treatment with tadalafil.
Moreover, tadalafil proved to be an alternative add-on
drug for patients with persistent storage LUTS refractory to
a1-adrenoceptor antagonists, even when compared with
solifenacin, thus confirming the valuable effect of tadalafil
on storage LUTS [26].
Patients in the TAM group retained the improvement of
Qmax achieved with combination therapy (13.97 at 12 wk vs
13.72 at 24 wk). Conversely, a decrease of Qmax was
observed in the TAD group (18.28 at 12 wk vs 15.87 at
24 wk); however, an improvement of Qmax from baseline
was also observed in the TAD group (14.0 vs 15.87 ml/s).
In contrast with our results, the first systematic
review by Laydner et al [27] on the use of PDE5-Is for
BPE-related LUTS reported that PDE5-Is improved IPSS
and IIEF-5 but not Qmax.
Moreover, in another meta-analysis, PDE5-Is were more
effective in association with ABs, improving IPSS (mean
difference –1.8), IIEF-5 score (mean difference +3.6), and
Qmax (mean difference +1.5 ml/s), when compared with
PDE5-Is alone, which improved IPSS and IIEF scores but
not Qmax [16].Please cite this article in press as: Sebastianelli A, et al. Which D
Tadalafil plus Tamsulosin for Men with Lower Urinary Tract S
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pooling four doses (2.5, 5, 10, and 20 mg), tadalafil failed
to produce a significant outcome in Qmax, whereas 5 mg/d
tadalafil therapy significantly improved Qmax (mean dif-
ference = +0.63 ml/s, p = 0.04).
As expected, only patients in the TAD group retained
the IIEF-5 improvement when compared with the TAM
group (16.96 vs 12.48; p = 0.003). Interestingly, the
impact of tadalafil on IIEF-5 was more pronounced, even
if not clinically significant, in combination with tamsu-
losin (+6.28 vs +4.64), suggesting a possible synergism
between these drugs. Indeed, a previous prospective ran-
domized study demonstrated that EF improved with
tamsulosin (+39.28% [p < 0.05]), tadalafil (+45.96%
[p < 0.05]), and tamsulosin and tadalafil combination
(+60.23% [p < 0.05]), with a better improvement seen
in combination therapy compared with single agent
alone. However, in line with our findings, the impact of
combination treatment on EF was significantly greater
than tamsulosin alone (p < 0.05) but not when compared
with tadalafil (p = 0.125) [28].
In our study, we described for the first time urinary and
sexual outcomes achieved within 12 wk of tamsulosin or
tadalafil monotherapy after a previous 12 wk of combina-
tion therapy, to achieve a tailored therapy based on
patients’ predominant symptoms and to reduce drugs’
intake.
As previously reported for the combination therapy of
tamsulosin and dutasteride, the withdrawal of tamsulosin
after 24 wk of combination therapy had no significant effect
on urinary outcomes. Indeed, LUTS relief was maintained in
the majority of patients after tamsulosin was removed from
combination, and the authors concluded that only patients
with severe symptoms may benefit from longer-term com-
bination therapy [29].
Even if combination therapy with tamsulosin and tada-
lafil achieved better urinary and sexual outcomes, after a
further 12 wk of monotherapy, both drugs were able to
preserve a significant recovery of urinary function from
baseline. Nevertheless, only patients treated with tadalafil
showed a satisfying sexual function and a better storage
IPSS at the end of the trial.
Daily doses of tadalafil 5 mg and tamsulosin 0.4 mg were
well tolerated. No patients discontinued the study because
of AEs. Headache was the main AE, with a higher incidence
in the TAM group (8%) as compared with the TAD group
(4%), suggesting that the use of tamsulosin can increase the
risk of this AE.
Strengths of the study are the prospective nature of the
trial and data collection together with the homogenous
population. However, this study may be restricted by some
limitations. Because this study was observational, it could
be prone to biases. Moreover, prostate size was not consid-
ered as inclusion/exclusion criteria or as a potential deter-
minant on the efficacy of therapy. Long-term follow-up is
also needed to better evaluate the role of a switching
approach versus a continuous treatment in terms of
patients’ compliance in term of symptoms, EF, urinary flow
management and costs.rug to Discontinue 3 Months After Combination Therapy of
ymptom and Erectile Dysfunction? Results of a Prospective
/j.euf.2019.09.015
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For men with LUTS and ED, combined treatment with
tamsulosin and tadalafil is well tolerated and effective. After
3 mo of combination therapy and consequent discontinua-
tion of tamsulosin, monotherapy with tadalafil was able to
further preserve the improvement of LUTS and EF although
with a slight decrease of Qmax. The possibility to switch from
a combination approach to a single-treatment strategy
seems a feasible option to improve patients’ compliance
and to better tailor LUTS treatment.
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